Analytical performance of the FDA-cleared Parsortix® PC1 system
{{output}}
Introduction: The Parsortix® PC1 system, Food and Drug Administration (FDA) cleared for use in metastatic breast cancer (MBC) patients, is an epitope-independent microfluidic device for the capture and harvest of circulating tum... ...
